Urticárias crônicas induzidas: atualização do tema
Chronic inducible urticaria: topic update
Sérgio Duarte Dortas Junior; Guilherme Gomes Azizi; Ana Carolina Miranda Sousa; Omar Lupi; Alfeu Tavares França; Solange Oliveira Rodrigues Valle
Resumo
A urticária é uma doença comum, determinada pela ativação de mastócitos que se apresenta por urticas, angioedema, ou ambos. Convencionou-se classificar a urticária, quanto a sua duração, em duas formas: aguda (UA) e crônica (UC). A urticária é definida como crônica quando persiste por 6 semanas ou mais. A urticária crônica compreende urticária crônica espontânea (UCE) e urticárias crônicas induzidas (UCInd), que incluem as urticárias físicas e não físicas. Estudos sugerem que a presença de UCInd associada a UCE está ligada a um pior prognóstico e duração da doença. Essa revisão tem por objetivo atualizar as informações disponíveis sobre a prevalência, quadros clínicos, métodos diagnósticos e tratamentos das UCInd por estímulos físicos ou não.
Palavras-chave
Abstract
Urticaria is a common disease determined by the activation of mast cells that presents with urticaria, angioedema, or both. According to its duration, urticaria is classified into two forms: acute (AU) and chronic (CU). Urticaria is defined as CU when it persists for 6 weeks or more. CU consists of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), which includes physical and nonphysical urticarias. Studies suggest that the presence of both CIndU and CSU is linked to worse prognosis and longer duration of these diseases. This review aims to update available information on the prevalence, clinical manifestations, diagnostic methods, and treatments of CIndU by physical or nonphysical stimuli.
Keywords
Referências
1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, BallmerWeber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018 Jul;73(7):1393-414.
2. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - TheEAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016 Jun;71(6):780-2.
3. Weller K, Altrichter S, Ardelean E, Krause K, Magerl M, Metz M, et al. Chronic urticaria. Prevalence, course, prognostic factors and impact. Hautarzt. 2010;61:750-7.
4. Sánchez-Borges M, González-Aveledo L, Caballero-Fonseca F, Capriles-Hulett A. Review of physical urticarias and testing methods. Curr Allergy Asthma Rep. 2017;17(8):51.
5. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387-91.
6. Kaplan AP, Gray L, Shaff RE, Horakova Z, Beaven MA. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy ClinImmunol. 1975;55(6):394-402.
7. Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, et al. Definition, aims, and implementation of GA²LEN urticaria centers of reference and excellence. Allergy. 2016:71;1210-8. Referências
8. Breathnach SM, Allen R, Ward AM, Greaves MW. Symptomatic dermographism: natural history, clinical features laboratory investigations and response to therapy. Clin Exp Dermatol. 1983;8:463-76.
9. Dice JP. Physical urticaria. Immunol Allergy Clin North Am. 2004;24:225-46.
10. Duke WW. Urticaria caused specifically by the action of physical agents: (light, cold,heat, freezing, burns, mechanical irritation, and physical and mental exertion). J Am Med Assoc. 1924;83:3-9.
11. Abajian M, Schoepke N, Altrichter S, Zuberbier T, Maurer M. Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am. 2014;34:73‑88.
12. Soter NA, Wasserman SI. Physical urticaria/angioedema: an experimental model of mast cell activation in humans. J Allergy Clin Immunol. 1980;66:358-65.
13. Schoepke N, Abajian M, Church MK, Magerl M. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol. 2015;40:399‑403.
14. Magerl M, Schmolke J, Metz M, ZuberbierT, Siebenhaar F, Maurer M. Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol. 2009;34:e137‑e140.
15. Sharpe GR, Shuster S. The effect of cetirizine on symptoms and wealing in dermographic urticaria. Br J Dermatol. 1993;129:580‑3.
16. Krause K, Ardelean E, Kessler B, Magerl M, Metz M, Siebenhaar F, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy. 2010;65:1494-5.
17. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154:177-80.
18. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57‑62.
19. Valle SOR, Azizi GG, Dortas Junior SD. Chronic spontaneous urticária (CSU) associated with chronic inducible urticaria (CIndU): Efficacy of omalizumab. Volume 74, Issue S106. Special Issue: Abstracts from the European Academy of Allergy and Clinical Immunology Congress, 01-05 June 2019, Lisbon, Portugal.
20. Toda S, Takahagi S, Mihara S, Hide M. Six cases of antihistamineresistant dermographic urticaria treated with oral ciclosporin. Allergol Int. 2011;60:547-50.
21. Borzova E, Rutherford A, KonstantinouGN, Leslie KS, Grattan CE. Narrowb and ultraviolet B phototherapy is beneficial in antihistamineresistant symptomatic dermographism: a pilot study. J Am Acad Dermatol. 2008;59:752-7.
22. Adamski H, Viguier M. Solar urticaria. Ann Dermatol Venereol. 2012;139:324-8.
23. Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol. 1985;65:449-50.
24. Johnsson M, Falk ES, Volden G. UVB treatment of factitious urticaria. Photodermatol.1987;4:302-4.
25. Lawlor F, Black AK. Delayed pressure urticaria. Immunol Allergy Clin North Am. 2004;24:247-58.
26. Lawlor F, Black AK, Ward AM, Morris R, Greaves MW. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol. 1989;120:403-8.
27. Ryan TJ, Shim-Young N, Turk JL. Delayed pressure urticaria. Br J Dermatol.1968;80:485-90.
28. Barlow RJ, Ross EL, MacDonald D, Black AK, Greaves MW. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol. 1994;131:341-7.
29. Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol. 1988;18(6):1289‑98.
30. Barlow RJ, Warburton F, Watson K, Black AK, Greaves MW. Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. J Am Acad Dermatol. 1993;29:954-8.
31. Sanchez J, Amaya E, Acevedo A, Celis A, Caraballo D, Cardona R. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors. J Allergy Clin Immunol Pract. 2017;5:464-70.
32. Warin RP. A simple out-patient test for delayed pressure urticaria. Br J Dermatol. 1987;116(5):742-3.
33. França AT, Valle SOR. Urticária e angioedema: diagnóstico e tratamento. 3ª ed. Rio de Janeiro: Revinter; 2014.
34. Lawlor F. Cellular, molecular and therapeutic aspects of the physical urticarias. MD theses (Dublin); 1990.
35. Black AK, Lawlor F, Greaves MW. Consensus meeting on the definition of physical urticarias and urticarial vasculitis. Clin Exp Dermatol. 1996;21(6):424-6.
36. Nettis E, Colanardi MC, Soccio AL, Ferrannini A, Vacca A. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, doubleblind, placebo-controlled study. Br J Dermatol. 2006;155:1279-82.
37. Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol. 2003;112:212‑3.
38. Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy. 2000;55:203-4.
39. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154:177-80.
40. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010;65:138-9.
41. Rodriguez-Rodriguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Alvarez-Mon M. Successful treatment of severe delayed pressure angiooedema with omalizumab. Allergol Immunopathol (Madr). 2014;42:78-80.
42. Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol. 2016;175:404-6.
43. Grundmann SA, Kiefer S, Luger TA, Brehler R. Delayed pressure urticaria - dapsone heading for first-line therapy? J Dtsch Dermatol Ges. 2011;9:908-12.
44. Engler RJ, Squire E, Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol. 1995;74:155-9.
45. Swerlick RA, Puhar N. Delayed pressure urticaria: response to treatment with sul-fasalazine in a case series of seventeen patients. Dermatol Ther. 2015;28:318-22.
46. Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti-TNFalpha. J Allergy Clin Immunol. 2007;119:752-4.
47. Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, Gregoriou S, Makris M, Boucher W, et al. Theophylline as “add-on” therapy in patients with delayed pressure urticaria: a prospective self-controlled study. Int J Immunopathol Pharmacol. 2005;18:595‑602.
48. Magerl M, Pisarevskaja D, Staubach P, Martus P, Church MK, Maurer M. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. Br J Dermatol. 2012;166(5):1095-9.
49. Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Vieira Dos Santos R, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol. 2007;32(3):241-5.
50. Koeppel MC, Bertrand S, Abitan R, Signoret R, Sayag J. Urticaria caused by cold. 104 cases. Ann Dermatol Venereol. 1996;123(10):627-32.
51. Sánchez JM, Ramírez RH, Tamayo LM, Chinchilla CF, Cardona R. Cold urticaria: case series and literature review. Biomedica. 2011 Jun;31(2):168-77.
52. Wanderer AA, Hoffman HM. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am. 2004 May;24(2):259-86, vii.
53. Lemanske RF Jr, Bush RK. Cold urticaria in infectious mononucleosis. JAMA. 1982;247(11):1604.
54. Doeglas HM, Rijnten WJ, Schröder FP, Schirm J. Cold urticaria and virus infections: a clinical and serological study in 39 patients. Br J Dermatol. 1986;114(3):311-8.
55. Metz M, Schütz A, Weller K, Gorczyza M, Zimmer S, Staubach P, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017 Sep;140(3):864-7.e5.
56. Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638‑49.
57. Pezzolo E, Peroni A, Gisondi P, Girolomoni G. Heat urticaria: a revision of published cases with an update on classification and management. Br J Dermatol. 2016;175(3):473-8.
58. Azizi GG, Dortas Junior SD, Zylbersztejn SRS, Rosa M, Tavares JVV, Valle SOR. TempTest: uma ferramenta de precisão na urticária física. Arq Asma Alerg Imunol. 2019;3(Supl 1):S208.
59. Pérez-Ferriols A, Barnadas M, Gardeazábal J, de Argila D, Carrascosa JM, Aguilera P, et al. Solar urticaria: Epidemiology and clinical phenotypes in a Spanish series of 224 patients. Actas Dermosifiliogr. 2017;108(2):132-9.
60. Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol. 2008;159:192-7.
61. Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, et al. Omalizumab for the treatment of solar urticaria: case series and systematic review of the literature. J Allergy Clin Immunol Pract. 2018 Mar. pii: S2213-2198(18)30132-6.
62. Azizi GG, Ontiveros CM, Zylbersztejn SRS, Dortas Junior SD, Valle SOR. Teste de urticária colinérgica modificado e teste de urticária vibratória em hospital universitário. Arq Asma Alerg Imunol. 2019;3(Supl 1):S209.
63. Ting S, Reimann BE, Rauls DO, Mansfield LE. Nonfamilial, vibration-induced angioedema. J Allergy Clin Immunol. 1983 Jun;71(6):546‑51.
64. Pressler A, Grosber M, Halle M, Ring J, Brockow K. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clin Exp Dermatol. 2013;38:151-3.
65. Seize MB, Ianhez M, de Souza PK, Rotta O, Cestari CS. Familial aquagenic urticaria: report of two cases and literatura review. An Bras Dermatol. 2009;84:530-3.
66. Shelley WB, Rawnsley HM. Aquagenic urticaria. Contact sensitivity reaction to water. JAMA. 1964;189:895-8.
67. Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Urticaria and angioedema: an update on classification and pathogenesis. Clin Rev Allergy Immunol. 2018;54(1):88-101.
68. Pitarch G, Torrijos A, Martinez-Menchon T, Sanchez-Carazo JL, Fortea JM. Familial aquagenic urticaria and Bernard-Soulier syndrome. Dermatology. 2006;212:96-7.
69. Czarnetzki BM, Breetholt KH, TraupeH. Evidence that water acts as a carrier for an epidermal antigen in aquagenic urticaria. J Am Acad Dermatol. 1986;15:623-7.
70. Sibbald RG, Black AK, Eady RA, James M, Greaves MW. Aquagenic urticaria: evidence of cholinergic and histaminergic basis. Br J Dermatol. 1981;105(3):297-302.
71. Parker RK, Crowe MJ, Guin JD. Aquagenic urticaria. Cutis. 1992;50:283-4.
72. Martinez-Escribano JA, Quecedo E, DelaCuadra J, Frias J,SanchezPedreno P, Aliaga A. Treatment of aquagenic urticaria with PUVA and astemizole. J Am Acad Dermatol. 1997;36:118-9.
73. Yavuz ST, Sahiner UM, Tuncer A, Sackesen C. Aquagenic urticaria in 2 adolescents. J Investig Allergol Clin Immunol. 2010;20:624‑5.
74. Park H, Kim HS, Yoo DS, Kim JW, Kim CW, Kim SS, et al. Aquagenic urticaria: areport of two cases. Ann Dermatol. 2011;23(Suppl. 3):S371-S374.
75. Czarnetzki BM. Ketotifen in cholinergic urticaria. J Allergy Clin Immunol. 1990;86:138-9.
76. Illig L. On the pathogenesis of cholinergic urticaria. I. Clinical observations and histological studies. Arch Klin Exp Dermatol. 1967;229:231-7.
77. Illig L, Heinicke A. On the pathogenesis of cholinergic urticaria. II. Studies on the relationships of cholinergic urticaria to sweat secretions with the help of various cholinomimetics. Arch Klin Exp Dermatol. 1967;229:285-99.
78. Illig L, Heinicke A. On the pathogenesis of cholinergic urticaria. 3. The influence of sweat secretion inhibition on cholinergic urticaria. Arch Klin Exp Dermatol. 1967;229:345-59.
79. Illig L, Heinicke A. On the pathogenesis of cholinergic urticaria. IV. On the problem of a true antigen-antibody reaction. Arch Klin Exp Dermatol. 1967;229:360-71.
80. Illig L, Heinicke A. Pathogenesis of cholinergic urticaria. V. The pharmacologic reactivity of the Prausnitz-Kustner reaction and the origin of the antigen. Arch Klin Exp Dermatol. 1967;230:34-47.
81. Moore-Robinson M, Warin RP. Some clinical aspects of cholinergic urticaria. Br J Dermatol. 1968;80(12):794-9.
82. Fukunaga A, Bito T, Tsuru K, Oohashi A, Yu X, Ichihashi M, et al. Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol. 2005;116:397-402.
83. Nakazato Y, Tamura N, Ohkuma A, Yoshimaru K, Shimazu K. Idiopathic pure sudomotor failure: anhidrosis due to deficits in cholinergic transmission. Neurology. 2004;63(8):1476-80.
84. Hatakeyama M, Fukunaga A, Washio K, Ogura K, Yamada Y, Horikawa T, et al. Addition of lafutidine canimprove disease activity and lead to better quality oflife in refractory cholinergic urticaria unresponsive to histamine H1 antagonists. J Dermatol Sci. 2016;82(2):137-9.
85. Oda Y, Fukunaga A, Tsujimoto M, Hatakeyama M, Washio K, Nishigori C. Combined cholinergic urticaria and cold-induced cholinergic urticaria with acquired idiopathic generalized anhidrosis. Allergol Int. 2015;64(2):214-5.
86. Fukunaga A, Washio K, Hatakeyama M, Oda Y, Ogura K, Horikawa T, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management. Clin Auton Res. 2018;28(1):103‑13.
87. Kawakami Y, Gokita M, Fukunaga A, Nishigori C. Refractory case of adrenergic urticaria successfully treated with clotiazepam. J Dermatol. 2015;42(6):635-7.
88. Montgomery SL. Cholinergic urticaria and exercise-induced anaphylaxis. Curr Sports Med Rep. 2015;14:61-3.
89. Altrichter S, Salow J, Ardelean E, Church MK, Werner A, Maurer M. Development of a standardized pulse controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci. 2014;75(2):88-93.
90. Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of cetirizine incholinergic urticaria. Acta Derm Venereol. 1995;75:147-9.
91. Zuberbier T, Munzberger C, HausteinU, Trippas E, Burtin B, Mariz SD, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193:324-7.
92. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:247-9.
93. Kutlu A, Tanoglu A, Ozturk S. Healingeffects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints. Chin Med J (Engl). 2015;128:1559-60.
94. Otto HF, Calabria CW. A case of severe refractory chronic urticaria: a novel method for evaluation and treatment. Allergy Asthma Proc. 2009;30(3):333-7.
95. Ujiie H, Shimizu T, Natsuga K, Arita K, Tomizawa K, Shimizu H. Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines. Clin Exp Dermatol. 2006;31:588-9.
96. Feinberg JH, Toner CB. Successful treatment of disabling cholinergic urticaria. Mil Med. 2008;173:217-20.
97. Sheraz A, Halpern S. Cholinergic urticaria responding to botulinum toxin injection for axillary hyperhidrosis. Br J Dermatol. 2013;168:1369‑70.
98. Kozaru T, Fukunaga A, Taguchi K, OguraK, Nagano T, Oka M, et al. Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int. 2011;60:277-81.
99. Berth-Jones J, Graham-Brown RA. Cholinergic pruritus, erythema and urticaria: adisease spectrum responding to danazol. Br J Dermatol. 1989;121:235-7.
100. La Shell MS, England RW. Severe refractory cholinergic urticaria treated with dana-zol. J Drugs Dermatol. 2006;5:664-7.
101. Wong E, Eftekhari N, Greaves MW, Ward AM. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol.1987;116:553-6.
Submetido em:
10/06/2020
Aceito em:
18/08/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email